H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $41 from $40 and keeps a Buy rating on the shares following the Q3 report. Darzalex Faspro is now FDA approved in high-risk smoldering multiple myeloma, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating
- Genmab Reports Strong Revenue Growth and Strategic Advances
- Genmab Reports Strong Financial Growth and Announces Acquisition of Merus
- Genmab reports Q3 operating profit $459M, consensus $370.1M
- Genmab affirms 2025 revenue outlook $3.5B-$3.7B, consensus $3.7B